Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.75 - $41.6 $20.9 Million - $48.9 Million
1,174,700 New
1,174,700 $46.6 Million
Q3 2023

Nov 14, 2023

SELL
$10.13 - $13.98 $4.06 Million - $5.61 Million
-401,220 Reduced 37.9%
657,280 $7.53 Million
Q2 2023

Aug 14, 2023

BUY
$6.84 - $11.91 $471,960 - $821,790
69,000 Added 6.97%
1,058,500 $10.9 Million
Q1 2023

May 15, 2023

SELL
$7.0 - $8.75 $270,900 - $338,625
-38,700 Reduced 3.76%
989,500 $7.64 Million
Q4 2022

Feb 14, 2023

BUY
$5.45 - $7.35 $161,320 - $217,560
29,600 Added 2.96%
1,028,200 $7.56 Million
Q3 2022

Nov 14, 2022

BUY
$6.89 - $9.39 $241 - $328
35 Added 0.0%
998,600 $7.19 Million
Q2 2022

Aug 15, 2022

SELL
$6.71 - $9.52 $1.4 Million - $1.98 Million
-208,435 Reduced 17.27%
998,565 $8.5 Million
Q1 2022

May 16, 2022

SELL
$6.41 - $13.89 $884,580 - $1.92 Million
-138,000 Reduced 10.26%
1,207,000 $10.8 Million
Q4 2021

Feb 14, 2022

SELL
$10.41 - $13.95 $6.11 Million - $8.19 Million
-587,000 Reduced 30.38%
1,345,000 $18.6 Million
Q3 2021

Nov 15, 2021

BUY
$8.19 - $11.31 $3.58 Million - $4.94 Million
437,000 Added 29.23%
1,932,000 $20.6 Million
Q2 2021

Aug 16, 2021

SELL
$8.81 - $15.03 $140,960 - $240,480
-16,000 Reduced 1.06%
1,495,000 $13.5 Million
Q1 2021

May 17, 2021

BUY
$10.02 - $13.92 $2.64 Million - $3.66 Million
263,000 Added 21.07%
1,511,000 $16 Million
Q4 2020

Feb 16, 2021

BUY
$7.42 - $15.96 $3.25 Million - $6.99 Million
438,000 Added 54.07%
1,248,000 $15.7 Million
Q3 2020

Nov 16, 2020

BUY
$7.15 - $11.5 $5.79 Million - $9.32 Million
810,000 New
810,000 $7.12 Million

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.